Literature DB >> 24972967

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.

Ai-Na Liu1, Ping Sun, Jian-Nan Liu, Cai-Yan Yu, Hua-Jun Qu, Ai-Hong Jiao, Liang-Ming Zhang.   

Abstract

The objective of the present study was to investigate differences of serum protein mass spectrometry in patients with triple negative breast cancer (TNBC) and non-TNBC and thus to search for candidate serum protein biomarkers for identification and diagnosis of TNBC. Thirty serum samples from patients with TNBC without any treatment and 30 serum samples from patients with non-TNBC without any treatment were detected by using two-dimensional gel electrophoresis and matrix-assisted laser dissociation tandem time-of-flight mass spectrometry (MALDI-TOF-MS). PDQest 7.0 software of Bio-Rad was adopted to screen differentially expressed proteins. Protein ID retrieval was conducted by using Mascot software to confirm the results of differential proteins. Two-dimensional gel electrophoresis profiles were obtained successfully. A total of 16 differential protein loci were discovered by analyzing patient sera of the two groups using two-dimensional gel electrophoresis analysis software. Ten differential proteins were identified by mass spectrometric analysis in the 16 differential proteins. Combined with database and literature search results, it is speculated that the specifically upregulated proteins and downregulated proteins including transthyretin, haptoglobin, and antitrypsin may be the potential markers for early diagnosis of TNBC. Comparing the TNBC patients with the non-TNBC patients, there are differences in serum protein compositions. The ten differential proteins discovered in the present study provide reference basis for further improving early diagnosis and identification and diagnosis index of TNBC. Especially, transthyretin, haptoglobin, and antitrypsin show dramatic significances for the early diagnosis of TNBC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24972967     DOI: 10.1007/s13277-014-2221-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

2.  Serum biomarkers for detection of breast cancers: A prospective study.

Authors:  Carole Mathelin; Anne Cromer; Corinne Wendling; Catherine Tomasetto; Marie-Christine Rio
Journal:  Breast Cancer Res Treat       Date:  2006-03       Impact factor: 4.872

3.  Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.

Authors:  Charlotte H Clarke; Christine Yip; Donna Badgwell; Eric T Fung; Kevin R Coombes; Zhen Zhang; Karen H Lu; Robert C Bast
Journal:  Gynecol Oncol       Date:  2011-06-25       Impact factor: 5.482

4.  SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.

Authors:  Yue Hu; Suzhan Zhang; Jiekai Yu; Jian Liu; Shu Zheng
Journal:  Breast       Date:  2005-08       Impact factor: 4.380

5.  Prognostic markers in triple-negative breast cancer.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew R Green; Andrew H S Lee; John F Robertson; Ian O Ellis
Journal:  Cancer       Date:  2007-01-01       Impact factor: 6.860

6.  Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer.

Authors:  Eneida López-Árias; Adriana Aguilar-Lemarroy; Luis Felipe Jave-Suárez; Gilberto Morgan-Villela; Ignacio Mariscal-Ramírez; Moisés Martínez-Velázquez; Angel H Alvarez; Abel Gutiérrez-Ortega; Rodolfo Hernández-Gutiérrez
Journal:  Electrophoresis       Date:  2012-07       Impact factor: 3.535

Review 7.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

8.  Clinicopathological features and treatment strategy for triple-negative breast cancer.

Authors:  Yutaka Yamamoto; Hirotaka Iwase
Journal:  Int J Clin Oncol       Date:  2010-07-15       Impact factor: 3.402

9.  Proteomic analysis of serum in lung cancer induced by 3-methylcholanthrene.

Authors:  Minhua Li; Bo Ye; Yuxia Zhang; Honglei Chen; Dong Xia; Mingqiu Liu; Fei Yang
Journal:  J Biomed Biotechnol       Date:  2009-09-24
View more
  4 in total

1.  Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry.

Authors:  Dongjian Song; Lifang Yue; Junjie Zhang; Shanshan Ma; Wei Zhao; Fei Guo; Yingzhong Fan; Heying Yang; Qiuliang Liu; Da Zhang; Ziqiang Xia; Pan Qin; Jia Jia; Ming Yue; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Cancer Biol Ther       Date:  2016-06-03       Impact factor: 4.742

2.  Identification of potential serum proteomic biomarkers for clear cell renal cell carcinoma.

Authors:  Juan Yang; Jin Yang; Yan Gao; Lingyu Zhao; Liying Liu; Yannan Qin; Xiaofei Wang; Tusheng Song; Chen Huang
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

Review 3.  Circulating proteins as predictive and prognostic biomarkers in breast cancer.

Authors:  Yannick Bidet; Nina Radosevic-Robin; Xavier Durando; Hugo Veyssière; Frederique Penault-Llorca
Journal:  Clin Proteomics       Date:  2022-07-11       Impact factor: 5.000

4.  Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer.

Authors:  Jiande Wu; Tarun Karthik Kumar Mamidi; Lu Zhang; Chindo Hicks
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.